Profound thrombocytopenia in previously treated patients with recurrent ovarian carcinoma receiving topotecan.
Abendstein
B
B
Klingler
P J
PJ
Sevin
B U
BU
D000970:Antineoplastic Agents / Q000009:adverse effects; D001323:Autoantibodies / Q000097:blood*; D002277:Carcinoma / Q000188:drug therapy / Q000276:immunology*; D005260:Female; D006801:Humans; D007122:Immunoelectrophoresis; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000276:immunology*; D009474:Neurons / Q000276:immunology*; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000276:immunology*; D013921:Thrombocytopenia / Q000139:chemically induced / Q000276:immunology*; D019772:Topotecan / Q000009:adverse effects
D000970:Antineoplastic Agents; D001323:Autoantibodies; D019772:Topotecan